CN104116812B - A kind of medical composition and its use treating internal hemorrhage - Google Patents
A kind of medical composition and its use treating internal hemorrhage Download PDFInfo
- Publication number
- CN104116812B CN104116812B CN201410398046.3A CN201410398046A CN104116812B CN 104116812 B CN104116812 B CN 104116812B CN 201410398046 A CN201410398046 A CN 201410398046A CN 104116812 B CN104116812 B CN 104116812B
- Authority
- CN
- China
- Prior art keywords
- hemorrhage
- folium caryophylli
- internal hemorrhage
- pharmaceutical composition
- ethanol extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000032843 Hemorrhage Diseases 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000002671 adjuvant Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229940126701 oral medication Drugs 0.000 claims description 2
- 230000023597 hemostasis Effects 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 abstract description 2
- 230000009852 coagulant defect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000000740 bleeding effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000023555 blood coagulation Effects 0.000 description 8
- 206010053567 Coagulopathies Diseases 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 208000023329 Gun shot wound Diseases 0.000 description 1
- 241001299530 Leptodermis pilosa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229950006142 carbazochrome salicylate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- -1 correctives Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960004817 etamsylate Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CELKBRMLNUNCIP-HTFHIHPASA-M sodium;2-hydroxybenzoate;[(e)-(3-hydroxy-1-methyl-6-oxo-2,3-dihydroindol-5-ylidene)amino]urea Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O.NC(=O)N\N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 CELKBRMLNUNCIP-HTFHIHPASA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of medical composition and its use treating internal hemorrhage, said composition is prepared from by active component and adjuvant, and described active component is Folium Caryophylli ethanol extract.The pharmaceutical composition hemostasis of the present invention, coagulant effect significantly, can be used for the internal hemorrhage diseases such as serious obstinate dysfunctional uterine hemorrhage, digestive tract hemorrhage, and can be used for treating the various hemorrhages of conventional hemorrhage DeGrain.
Description
Technical field
The invention belongs to pharmaceutical technology field, in particular to a kind of medical composition and its use treating internal hemorrhage.
Background technology
Blood is the material that body weight for humans is wanted, all hemorrhage diseases, as the most effectively stopped blooding, causes blood to consume, and causes body weak, even threat to life, therefore the application of hemorrhage has great importance.Hemorrhage it is divided into external haemorrhage and internal hemorrhage two kinds.Blood flows to body epigenesist from wound and is referred to as external haemorrhage, be common in wound of lancinating, stab, gunshot wound and spreading wound etc..If skin does not has wound, blood is flowed in tissue, internal organs or body cavity by the blood vessel ruptured, referred to as internal hemorrhage.The reason causing internal hemorrhage is complexity far beyond external haemorrhage, processes the most difficult, needs to remove hospital therapy more.Blood is stopped, is the main purpose giving treatment to traumatic external haemorrhage.Different according to external haemorrhage kind, Hemostasis is the most different.Doing multiplex clinically is compressing and hemostasis with packs method, but this Hemostasis is not very convenient effectively.
In hemostatic agent, having several formulations perhaps, such as etamsylate, vitamin K, carbazochrome salicylate, GONGXUENING etc., these medicaments are conventional therapy medication or auxiliary medicine for treatment, and versatility is relatively strong, but drug effect is the most obvious.The course for the treatment of, longer curative effect was relatively slow, when conditions of patients is light, can obtain therapeutic effect, when conditions of patients is serious, was then difficult to obtain the effect of basic treatment.Some Western medicine synthesized by chemical substance has certain therapeutic effect, but Western medicine often toxic and side effects is relatively big, can stimulate stomach discomfort, and expensive.
Summary of the invention
In view of the deficiencies in the prior art, it is an object of the invention to provide a kind of haemostatic medicament treating internal hemorrhage.The hemostasis of this medicine, blood coagulation enhancing effect significantly, can be used for the internal hemorrhage disease such as metrorrhagia, digestive tract hemorrhage.
The object of the present invention is achieved like this:
A kind of pharmaceutical composition treating internal hemorrhage, is prepared from by active component and adjuvant, and described active component is Folium Caryophylli ethanol extract.The preferably described ethanol extraction that Folium Caryophylli ethanol extract is Folium Caryophylli.Wherein, Folium Caryophylli selects the leaf of Rubiaceae hair Flos syringae persicae Leptodermis pilosa (Franch.) Diels；Can be fresh goods, it is also possible to for wet product.
Further, the pharmaceutical composition of described treatment internal hemorrhage, Folium Caryophylli ethanol extract therein can be prepared as follows forming: is placed in extraction element by Folium Caryophylli, successively with the 85-90%(v/v of 8-15 times amount (v/w)) ethanol, 60-65%(v/v) alcohol reflux, united extraction liquid, filters, and reclaims ethanol and continues to be condensed into thick paste, it is dried, obtains Folium Caryophylli ethanol extract.
It should be noted that the pharmaceutical composition for the treatment of internal hemorrhage of the present invention, it is preferably prepared to oral formulations.Described oral formulations includes oral liquid, tablet, capsule, granule.According to the common process of formulation art, those skilled in the art is easy to the solid orally ingestible that the adjuvant that Folium Caryophylli ethanol extract is available with on pharmaceutics is prepared as commonly use, such as granule, tablet, capsule.Wherein, available on pharmaceutics adjuvant includes filler, disintegrating agent, binding agent, correctives, lubricant etc..
The present inventor is by finding after substantial amounts of experimental study, and Folium Caryophylli ethanol extract all can substantially shorten mice plasma recalcification time, clotting time and bleeding time, has significantly hemostasis, blood coagulation enhancing effect；It may be by activating endogenous and the multiple thrombin of exogenous cruor pathway, promoting thrombinogen and thromboplastin generation, the synthesis of accelerating fibers albumen, thus reaches hemostasis, the biological activity of coagulant.Based on above result of study, the present invention also provides for a kind of pharmaceutical applications, it may be assumed that Folium Caryophylli ethanol extract purposes in the oral drugs of preparation treatment internal hemorrhage.
Compared with prior art, the pharmaceutical composition hemostasis of the present invention, blood coagulation enhancing effect significantly, can be used for the internal hemorrhage diseases such as serious obstinate dysfunctional uterine hemorrhage, digestive tract hemorrhage, and can be used for treating the various hemorrhages of conventional hemorrhage DeGrain.
Detailed description of the invention
The following is preparation embodiment and the effect test example of Folium Caryophylli ethanol extract of the present invention, the present invention will be further explained, but this is not meant as protection scope of the present invention and is limited by below embodiment.
The preparation of embodiment 1 Folium Caryophylli ethanol extract
Folium Caryophylli dry product 2kg, puts in round-bottomed flask, is 90%(v/v by 20L concentration respectively) ethanol and 65%(v/v) each reflux, extract, of ethanol 2 times, each 4h, pour out alcohol extract.Merge 4 extracting solution, filter, reclaim ethanol and continue to be condensed into thick paste, 70 DEG C of drying under reduced pressure, be ground into fine powder, cross 100 mesh sieves, obtain Folium Caryophylli ethanol extract.
The preparation of embodiment 2 Folium Caryophylli ethanol extract
Folium Caryophylli dry product 1kg, puts in round-bottomed flask, is 85%(v/v by 13L concentration respectively) ethanol and 60%(v/v) each reflux, extract, of ethanol 2 times, each 4h, pour out alcohol extract.Merge 4 extracting solution, filter, reclaim ethanol and continue to be condensed into thick paste, 70 DEG C of drying under reduced pressure, be ground into fine powder, cross 100 mesh sieves, obtain Folium Caryophylli ethanol extract.
Embodiment 3 mice plasma recalcification time is tested
SPF level NIH kind mice 36, weight 18-22g, it is randomly divided into 3 groups, male and female half and half, be respectively that matched group (15mL/kg normal saline), Folium Caryophylli ethanol extract be low, high dose group (give the Folium Caryophylli ethanol extract of the embodiment of the present invention 1 preparation, dosage is respectively 65,130mg/kg), gastric infusion, 1 time/d, continuous 7d.1h after being administered in the 7th day, wins eyeball and takes blood 1mL, put into the centrifuge tube added with liquor sodii citratis, be centrifuged 10 with 3000r/min
Min, separated plasma is standby.Take upper plasma 0.1mL in test tube, put into incubation 2min in 37 DEG C of water-baths, be subsequently adding 0.25mol/L calcium chloride solution 0.1mL；Place into after mixing in 37 DEG C of water-baths, start simultaneously at timing.Test tube is slowly tilted 1 time every 15s after 1min.Record from add calcium chloride solution to fibrin solidification, the motionless required time of liquid level, be blood plasma recalcification time (PRT).
PRT LVFS=(matched group PRT-administration group PRT)/matched group PRT × 100%
Folium Caryophylli ethanol extract the results are shown in Table 1 to the impact of mice PRT.Result shows, compares with matched group, and medicine is low, high dose group all can significantly shorten PRT(P＜ 0.01), and shorten with the increase of dosage, this imply that the Folium Caryophylli ethanol extract of the present invention has hemostasis, blood coagulation enhancing effect.
Table 1 is respectively organized mice plasma recalcification time and is compared
| Group | Sample size | PRT(s) | PRT LVFS (%) |
| Matched group | 12 | 98.0±13.1 | - |
| Medicine high dose group | 12 | 64.9±9.6## | 33.8 |
| Medicine low dose group | 12 | 73.2±10.5## | 25.3 |
Compare with matched group,# P＜ 0.05,## P＜ 0.01.
Embodiment 4 clotting time of mice is tested
SPF level NIH kind mice 36, weight 18-22g, it is randomly divided into 3 groups, male and female half and half, be respectively that matched group (15mL/kg normal saline), Folium Caryophylli ethanol extract be low, high dose group (give the Folium Caryophylli ethanol extract of the embodiment of the present invention 1 preparation, dosage is respectively 65,130mg/kg), gastric infusion, 1 time/d, continuous 7d.After being administered 30min in the 7th day, carry out as follows: 1. capillary glass-tube method: insert mice endocanthion eyeball rear vein beard with capillary glass-tube and take blood, till reaching 5cm blood post.Fracture little section of capillary glass-tube one every 30s, check for blood clotting silk and occur；Record is taken a blood sample to from capillary glass-tube and the time of blood clotting silk is occurred, is clotting time CT1.2. slide method: win rapidly side eyeball with the curved tweezer of ophthalmology, i.e. has blood to flow out；Bleeding in each one, microscope slide two ends, drop of blood diameter is about 5mm, uses manual time-keeping immediately；Provoke once the most gently from drop of blood edge every 30s cleaning pin, and observe and provoke with or without the blood streak；Start to only provoking the blood streak from blood sampling, between being lasted, be clotting time CT2；Another is bled and reviews for last.
CT LVFS=(matched group CT-administration group CT)/matched group CT × 100%
Folium Caryophylli ethanol extract the results are shown in Table 2 to the impact of clotting time of mice, table 3.Result shows, compares with matched group, and medicine is low, high dose group all can significantly shorten PRT(P＜ 0.05 orP＜ 0.01), and shorten with the increase of dosage, this also imply that the Folium Caryophylli ethanol extract of the present invention has hemostasis, blood coagulation enhancing effect.
Table 2 is respectively organized mice capillary glass-tube method clotting time and is compared
| Group | Sample size | CT1(s) | CT1 LVFS (%) |
| Matched group | 12 | 159.6±22.5 | - |
| Medicine high dose group | 12 | 105.8±13.7## | 33.7 |
| Medicine low dose group | 12 | 134.7±16.3# | 15.6 |
Compare with matched group,# P＜ 0.05,## P＜ 0.01.
Table 3 is respectively organized mice slide method clotting time and is compared
| Group | Sample size | CT2(s) | CT2 LVFS (%) |
| Matched group | 12 | 251.7±24.4 | - |
| Medicine high dose group | 12 | 179.0±16.8## | 28.9 |
| Medicine low dose group | 12 | 203.2±19.5## | 19.3 |
Compare with matched group,# P＜ 0.05,## P＜ 0.01.
The embodiment 5 mice bleeding time tests
SPF level NIH kind mice 36, weight 18-22g, it is randomly divided into 3 groups, male and female half and half, be respectively that matched group (15mL/kg normal saline), Folium Caryophylli ethanol extract be low, high dose group (give the Folium Caryophylli ethanol extract of the embodiment of the present invention 1 preparation, dosage is respectively 65,130mg/kg), gastric infusion, 1 time/d, continuous 7d.After being administered 30min in the 7th day, cut off Mouse Tail-tip about 3mm, timing immediately, treat that blood overflows voluntarily；Every 30s filter paper gentle aspiration drop of blood, be artificially formed wound surface to stopped bleeding institute through the time as bleeding time, record bleeding time (BT).
BT LVFS=(matched group BT-administration group BT)/matched group BT × 100%
Folium Caryophylli ethanol extract the results are shown in Table 4 to the impact in mice bleeding time.Result shows, compares with matched group, medicine is low, high dose group all can significantly shorten the docking bleeding time (P＜ 0.05 orP＜ 0.01), and the bleeding time shorten with the increase of dosage, this also imply that the Folium Caryophylli ethanol extract of the present invention has hemostasis, blood coagulation enhancing effect.
Table 4 is respectively organized the mice bleeding time and is compared
| Group | Sample size | BT(s) | BT LVFS (%) |
| Matched group | 12 | 662.5±70.5 | - |
| Medicine high dose group | 12 | 374.0±33.6## | 43.5 |
| Medicine low dose group | 12 | 583.7±48.6# | 11.9 |
Compare with matched group,# P＜ 0.05,## P＜ 0.01.
Claims (5)
1. treat a pharmaceutical composition for internal hemorrhage, active component and adjuvant be prepared from, it is characterised in that: described active component is the ethanol extraction of Folium Caryophylli.
Treat the pharmaceutical composition of internal hemorrhage the most according to claim 1, it is characterized in that: described Folium Caryophylli ethanol extract is prepared as follows forming: be placed in extraction element by Folium Caryophylli, successively with the 85-90%(v/v of 8-15 times amount (v/w)) ethanol, 60-65%(v/v) alcohol reflux, united extraction liquid, filter, reclaim ethanol and continue to be condensed into thick paste, being dried, obtain Folium Caryophylli ethanol extract.
Treat the pharmaceutical composition of internal hemorrhage the most according to claim 1, it is characterised in that: described pharmaceutical composition is oral formulations.
Treat the pharmaceutical composition of internal hemorrhage the most according to claim 3, it is characterised in that: described oral formulations includes oral liquid, tablet, capsule, granule.
5. the ethanol extraction of Folium Caryophylli purposes in the oral drugs of preparation treatment internal hemorrhage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410398046.3A CN104116812B (en) | 2014-08-14 | 2014-08-14 | A kind of medical composition and its use treating internal hemorrhage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410398046.3A CN104116812B (en) | 2014-08-14 | 2014-08-14 | A kind of medical composition and its use treating internal hemorrhage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104116812A CN104116812A (en) | 2014-10-29 |
| CN104116812B true CN104116812B (en) | 2016-08-17 |
Family
ID=51762592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410398046.3A Active CN104116812B (en) | 2014-08-14 | 2014-08-14 | A kind of medical composition and its use treating internal hemorrhage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104116812B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109432175A (en) * | 2018-12-27 | 2019-03-08 | 大理大学 | The preparation method and antimalarial purposes of river Yunnan open country Flos Caryophylli extract and its pharmaceutical composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1279950A (en) * | 1999-03-01 | 2001-01-17 | 中国科学院成都生物研究所 | Sigma-receptor acting medicine with triterpene compound structure |
| CN1739649A (en) * | 2005-09-11 | 2006-03-01 | 王浩贵 | Externally applied wound treating medicine of miquel brookweed |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2929945B1 (en) * | 2008-04-11 | 2010-09-03 | Inst Rech Developpement Ird | PROCESS FOR EXTRACTING MANGIFERIN AND ISOMANFIGERIN |
-
2014
- 2014-08-14 CN CN201410398046.3A patent/CN104116812B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1279950A (en) * | 1999-03-01 | 2001-01-17 | 中国科学院成都生物研究所 | Sigma-receptor acting medicine with triterpene compound structure |
| CN1739649A (en) * | 2005-09-11 | 2006-03-01 | 王浩贵 | Externally applied wound treating medicine of miquel brookweed |
Non-Patent Citations (1)
| Title |
|---|
| 藕节炒炭浸出物、3-表白桦脂酸、HPLC特征图谱变化;刘善新等;《中华中医药杂志（原中国医药学报）》;20130131;第28卷(第1期);第71-74页，尤其是第72页左栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104116812A (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100406902B1 (en) | Extracts from crude drug having an activity of treating injury and health food or animal feed comprising the same | |
| CN102631417B (en) | Traditional Chinese medicine extract for haemostasis and preparation method thereof | |
| CN105663000A (en) | Rhizome bletillae moisturizing gel product and preparation method thereof | |
| CN102274260B (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
| CN104116812B (en) | A kind of medical composition and its use treating internal hemorrhage | |
| CN102940854A (en) | Traditional Chinese medicine composition for facilitating wound healing after surgical operations, preparation process and application | |
| CN111297910A (en) | Application of maggot in preparing medicine for preventing and treating hyperplasia of mammary glands | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN108434166A (en) | A kind of " Xuesaitong Injection " pharmaceutical composition and preparation method thereof, preparation and application | |
| CN107596132A (en) | It is a kind of to be used to treat burn, pharmaceutical composition of scald and its preparation method and application | |
| CN103041031A (en) | Traditional Chinese medicine composition as well as preparation method and use thereof | |
| Zhu et al. | Hemocoagulase in abdominal operation and its effect on hemoagglutination | |
| CN102940669B (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN1329069C (en) | Hemostatic mastic and formulating method thereof | |
| CN105748553A (en) | Traditional Chinese medicinal composition for invigorating blood circulation, eliminating swelling and detoxifying, and preparation method thereof | |
| CN101416912B (en) | Hemostasia products | |
| CN104887879B (en) | Application of the Sa 13 taste roc bird balls of heat in preparation treatment osteoporosis agents | |
| CN104107219B (en) | A kind of aerosol and its preparation process for treating coronary disease and angina pectoris | |
| CN104055811A (en) | Hemostatic traditional Chinese medicine preparation | |
| CN109248269A (en) | A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands | |
| CN102716377B (en) | Medicament for treating ovarian hypofunction and sexual debility | |
| CN106511394A (en) | Novel application of fatty oil extract of aspongopus | |
| CN104721371A (en) | Styptic preparation and preparation method thereof | |
| CN104069186B (en) | A kind of pharmaceutical composition and application thereof preventing and treating cerebral thrombosis | |
| CN100594923C (en) | A kind of oral pharmaceutical composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Binwu Inventor before: Li Jian |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160531 Address after: 230000 Luyang, Anhui District, Hefei Road, No. 368 Applicant after: Chen Binwu Address before: Jinghu District of Anhui city of Wuhu province Jiuhua Road 241000 No. 263 Wuhu Second People's Hospital Applicant before: Li Jian |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Jiang Wenlong Inventor before: Chen Binwu |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170323 Address after: High Bay 061300 Cangzhou city of Hebei province Haixing County Luan Chuang-tzu Village No. 138 Patentee after: Jiang Wenlong Address before: 230000 Luyang, Anhui District, Hefei Road, No. 368 Patentee before: Chen Binwu |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180613 Address after: 330100 No. 10, Xiong Jia village, Xinjian County, Nanchang, Jiangxi Patentee after: Liu Yanfang Address before: 061300 Luan Chuang-tzu village, Gao Wan Town, Haixing County, Cangzhou, Hebei, 138 Patentee before: Jiang Wenlong |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181119 Address after: 409100 First Floor of Litangba Building, Nanbin Street, Shizhu Tujia Autonomous County, Chongqing Patentee after: Shizhu Tujia Autonomous County Balong Agricultural Development Co.,Ltd. Address before: 330100 No. 10, Xiong Jia village, Xinjian County, Nanchang, Jiangxi Patentee before: Liu Yanfang |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240930 Address after: 409100 chuncaoba street, Nanbin Town, Shizhu Tujia Autonomous County, Chongqing (bureau of Agriculture) Patentee after: Chongqing Shizhu Agricultural Development Co.,Ltd. Country or region after: China Address before: 409100 First Floor of Litangba Building, Nanbin Street, Shizhu Tujia Autonomous County, Chongqing Patentee before: Shizhu Tujia Autonomous County Balong Agricultural Development Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |